

Mouse Anti-VHL (Von Hippel Lindau) [VHL40]: MC0556, MC0556RTU7

Intended Use: For Research Use Only

Description: Individuals harboring germline mutations in the tumor suppressor gene von Hippel-Lindau (VHL) exhibit an increased susceptibility to a variety of tumors, including renal carcinoma, hemangioblastoma of the central nervous system and pheochromocytoma. The Elongin (SIII) complex has been identified as the functional target of the VHL protein. Elongin (SIII) is a heterotrimer composed of a transcriptional active subunit designated Elongin A, and two regulatory subunits designated Elongin B and Elongin C. VHL functions by binding to the Elongin B and C subunits, inhibiting the transcriptional efficacy of the Elongin (SIII) complex. Different isoforms of VHL have been observed, encoded by alternatively spliced transcript variants. The molecular weight of each isoform varies between species.


Specifications

Clone: VHL40
 Source: Mouse
 Isotype: IgG1k
 Reactivity: Human, mouse, rat
 Immunogen: Human VHL aa 54-213
 Localization: Cytoplasm and/or membrane
 Formulation: Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN₃)
 Storage: Store at 2°- 8°C
 Applications: IHC, IF, IP, WB
 Package:

Description	Catalog No.	Size
VHL Concentrated	MC0556	1 ml
VHL Prediluted	MC0556RTU7	7 ml

IHC Procedure

Positive Control Tissue: Gall bladder
 Concentrated Dilution: 25-200
 Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual
 * Result should be confirmed by an established diagnostic procedure.



FFPE human kidney stained with anti-VHL using DAB showing cytoplasmic staining of cells in glomeruli

References:

1. Establishment of xenografts of urological cancers on chicken chorioallantoic membrane (CAM) to study metastasis. Hu J, et al. *Precis Clin Med* 2:140-151, 2019.
2. VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2. Gao YH, et al. *Nat Commun* 8:15337, 2017.
3. Somatic VHL Mutation in a Patient With MEN1-Associated Metastatic Pancreatic Neuroendocrine Tumor Responding to Sunitinib Treatment: A Case Report. Shell J, et al. *J Endocr Soc* 1:1124-1134, 2017..
4. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma. Zhao Z, et al. *Mol Med Rep* 14:2785-90, 2016.